Compare · EPZM vs SLRX
EPZM vs SLRX
Side-by-side comparison of Epizyme Inc. (EPZM) and Salarius Pharmaceuticals Inc. (SLRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPZM and SLRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- EPZM is the larger of the two at $110.1M, about 5.7x SLRX ($19.4M).
- EPZM has more recent analyst coverage (5 ratings vs 2 for SLRX).
- Company
- Epizyme Inc.
- Salarius Pharmaceuticals Inc.
- Price
- $1.47-1.01%
- $0.82+36.55%
- Market cap
- $110.1M
- $19.4M
- 1M return
- -
- -3.57%
- 1Y return
- -
- -92.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 2
Epizyme Inc.
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Latest EPZM
- FDA Approval for TAZVERIK issued to EPIZYME INC
- FDA Approval for TAZVERIK issued to EPIZYME INC
- SEC Form SC 13G/A filed by Epizyme Inc. (Amendment)
- Looking Into Epizyme's Return On Capital Employed
- SEC Form 15-12G filed by Epizyme Inc.
- SEC Form EFFECT filed by Epizyme Inc.
- SEC Form EFFECT filed by Epizyme Inc.
- SEC Form EFFECT filed by Epizyme Inc.
- SEC Form 4: Giordano Michael F returned 17,054 shares to the company, closing all direct ownership in the company
- SEC Form 4: Goldfischer Carl returned 3,403,005 shares to the company, closing all direct ownership in the company
Latest SLRX
- SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)
- SEC Form 8-K filed by Salarius Pharmaceuticals Inc.
- SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting